Alzheimer's disease dementia is characterized by a dysfunction of cortical transmission mainly due to acetylcholine deficit. So far, current pharmacological treatments of Alzheimer's disease act by potentiating this cholinergic transmission and hence improve cognitive functions. Dopamine is another key neurotransmitter acting as an important modulator of brain activity. Interestingly, recent works showed that drugs acting on the dopamine receptors may strongly modulate cortical plasticity mechanisms and cognitive performances in Alzheimer's disease dementia. The primary objective of this project is to propose a new pharmacological treatment based on dopaminergic agonist rotigotine, associated to cholinesterase inhibitors, in patients who have mild Alzheimer's disease. Neurophysiological investigations will allow us to identify quantifiable biomarkers underlying the effects induced by dopamine on the neurodegenerative brain. The findings yielded by the present project will have a potential immediate impact on clinical treatment of Alzheimer's disease patients. Since dopaminergic drugs are well tolerated and relatively cheap, a positive result could lead to a fast transfer of the present proposal to the clinical experience. This could provide alternative treatment for cognitive dysfunction in Alzheimer's disease patients and even delay disease progression.